WallStSmart

Thermo Fisher Scientific Inc (TMO)vsWelltower Inc (WELL)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Thermo Fisher Scientific Inc generates 311% more annual revenue ($44.56B vs $10.84B). TMO leads profitability with a 15.0% profit margin vs 8.6%. TMO appears more attractively valued with a PEG of 1.76. TMO earns a higher WallStSmart Score of 59/100 (C).

TMO

Buy

59

out of 100

Grade: C

Growth: 4.7Profit: 7.0Value: 7.3Quality: 6.3
Piotroski: 3/9

WELL

Hold

39

out of 100

Grade: F

Growth: 7.3Profit: 4.0Value: 2.0Quality: 7.5
Piotroski: 4/9Altman Z: 1.20
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

TMOSignificantly Overvalued (-27.5%)

Margin of Safety

-27.5%

Fair Value

$384.82

Current Price

$490.77

$105.95 premium

UndervaluedFair: $384.82Overvalued
WELLSignificantly Overvalued (-2052.0%)

Margin of Safety

-2052.0%

Fair Value

$9.66

Current Price

$196.73

$187.07 premium

UndervaluedFair: $9.66Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

TMO3 strengths · Avg: 8.3/10
Market CapQuality
$182.14B9/10

Large-cap with strong market position

Operating MarginProfitability
21.2%8/10

Strong operational efficiency at 21.2%

Free Cash FlowQuality
$2.99B8/10

Generating 3.0B in free cash flow

WELL2 strengths · Avg: 9.5/10
Revenue GrowthGrowth
41.3%10/10

Revenue surging 41.3% year-over-year

Market CapQuality
$137.19B9/10

Large-cap with strong market position

Areas to Watch

TMO3 concerns · Avg: 3.7/10
PEG RatioValuation
1.764/10

Expensive relative to growth rate

P/E RatioValuation
27.6x4/10

Moderate valuation

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

WELL4 concerns · Avg: 2.3/10
Return on EquityProfitability
2.5%3/10

ROE of 2.5% — below average capital efficiency

PEG RatioValuation
3.622/10

Expensive relative to growth rate

P/E RatioValuation
138.5x2/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
-26.3%2/10

Earnings declined 26.3%

Comparative Analysis Report

WallStSmart Research

Bull Case : TMO

The strongest argument for TMO centers on Market Cap, Operating Margin, Free Cash Flow.

Bull Case : WELL

The strongest argument for WELL centers on Revenue Growth, Market Cap. Revenue growth of 41.3% demonstrates continued momentum.

Bear Case : TMO

The primary concerns for TMO are PEG Ratio, P/E Ratio, Piotroski F-Score.

Bear Case : WELL

The primary concerns for WELL are Return on Equity, PEG Ratio, P/E Ratio. A P/E of 138.5x leaves little room for execution misses.

Key Dynamics to Monitor

TMO profiles as a value stock while WELL is a hypergrowth play — different risk/reward profiles.

TMO carries more volatility with a beta of 0.97 — expect wider price swings.

WELL is growing revenue faster at 41.3% — sustainability is the question.

TMO generates stronger free cash flow (3.0B), providing more financial flexibility.

Bottom Line

TMO scores higher overall (59/100 vs 39/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Thermo Fisher Scientific Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Thermo Fisher Scientific is an American provisioner of scientific instrumentation, reagents and consumables, and software and services to healthcare, life science, and other laboratories in academia, government, and industry (including in the biotechnology and pharmaceutical sectors). Based in Waltham, Massachusetts, Thermo Fisher was created in 2006 by the merger of Thermo Electron and Fisher Scientific, to form a company with US$ 9 billion in combined revenues.

Visit Website →

Welltower Inc

REAL ESTATE · REIT - HEALTHCARE FACILITIES · USA

Welltower Inc. is a real estate investment trust that invests in healthcare infrastructure.

Visit Website →

Want to dig deeper into these stocks?